EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 559 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion... January 7, 2021 FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer January 17, 2025 Junk food marketing restrictions: so near and yet so far December 15, 2022 Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS... July 7, 2025 Load more HOT NEWS Ventana HER2 Dual ISH Assay, A New Diagnostic Tool From Roche,... Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer Spring Budget 2023: What does it mean for the mission to... How Cancer Survivorship Has Changed Over 25 Years: An Expert Perspective
